Preparation of polymer microspheres capable for pioglitazone release to modify macrophages function.

BMDM, mouse bone marrow derived-macrophage DDW, double-distilled water Drug delivery system ELISA, enzyme-linked immunosorbent assay FBS, fetal bovine serum HPLC, high performance liquid chromatography IL, interleukin IMDM, Iscove's modified Dulbecco's medium M-CSF, macrophage colony stimulating factor Macrophages Microspheres PBS, phosphate buffered-saline solution PCR, polymerase chain reaction PGA, poly(glycolic acid) PLA, poly(l-lactic acid) PLGA PLGA, poly(L-lactic-co-glycolic acid) PPARγ, peroxisome proliferator-activated receptor γ Pioglitazone Poly(L-lactic-co-glycolic acid) RS, resulting solution SD, standard deviation SEM, scanning electron microscopy TNF, tumor necrosis factor UV, ultra violet iNOS, inducible nitric oxide synthase pio-MS, PLGA microspheres incorporating pioglitazone

Journal

Regenerative therapy
ISSN: 2352-3204
Titre abrégé: Regen Ther
Pays: Netherlands
ID NLM: 101709085

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 18 03 2019
revised: 12 06 2019
accepted: 25 06 2019
entrez: 25 7 2019
pubmed: 25 7 2019
medline: 25 7 2019
Statut: epublish

Résumé

Macrophages play an important role in regulating inflammation and tissue regeneration. It is known that anti-inflammatory macrophages play an important role for tissue regeneration. The objective of this study is to modify macrophages phenotypes for anti-inflammatory function by utilizing drug delivery technology. In this study, 4 types of poly (L-lactic-co-glycolic acid) (PLGA) microspheres incorporating pioglitazone of an anti-inflammatory modifier (pio-MS) with different sizes were prepared. In vitro release test of pio-MS was performed in phosphate buffered-saline solution (PBS) containing 1 wt% of sodium lauryl sulfate. The arginase activity and the secretion of interleukin (IL)-10 as anti-inflammatory macrophage markers of mouse bone marrow derived-macrophages (BMDM) cultured with the pio-MS were evaluated. The sustained release of pioglitazone was observed from all types of pio-MS in vitro. When BMDM were cultured with the pio-MS with an average diameter of 40 μm (pio-MS40), the arginase activity and the secretion of IL-10 increased to a significant extent compared with other pio-MS. The pio-MS40 with an diameter of 40 μm had a potential to induce the anti-inflammatory modification of BMDM in this culture system. The sustained release of pioglitazone is promoting to modify the macrophage function.

Identifiants

pubmed: 31338392
doi: 10.1016/j.reth.2019.06.008
pii: S2352-3204(19)30034-3
pmc: PMC6626069
doi:

Types de publication

Journal Article

Langues

eng

Pagination

131-138

Références

Int J Pharm. 2011 Aug 30;415(1-2):34-52
pubmed: 21640806
Expert Rev Mol Med. 2011 Jul 11;13:e23
pubmed: 21740602
J Pharm Sci. 2008 Jun;97(6):2022-35
pubmed: 17828755
Anesth Analg. 2011 Aug;113(2):398-404
pubmed: 21490083
Curr Opin Lipidol. 2003 Oct;14(5):459-68
pubmed: 14501584
Colloids Surf B Biointerfaces. 2017 Nov 1;159:217-231
pubmed: 28797972
Cell Metab. 2007 Aug;6(2):137-43
pubmed: 17681149
J Control Release. 2012 Jul 20;161(2):505-22
pubmed: 22353619
Immunity. 2010 Nov 24;33(5):699-712
pubmed: 21093321
Crit Rev Ther Drug Carrier Syst. 2013;30(3):257-76
pubmed: 23614648
Cell. 2005 Dec 16;123(6):993-9
pubmed: 16360030
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Nat Rev Immunol. 2003 Jan;3(1):23-35
pubmed: 12511873
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
Int J Mol Sci. 2014 Feb 28;15(3):3640-59
pubmed: 24590126
Biochem Biophys Res Commun. 2012 Sep 14;426(1):76-82
pubmed: 22910418
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
J Biomed Mater Res A. 2016 Apr;104(4):942-56
pubmed: 26704185
Nihon Rinsho. 2010 Feb;68(2):278-83
pubmed: 20158097
J Biomed Mater Res B Appl Biomater. 2017 Aug;105(6):1692-1716
pubmed: 27098357
Biomater Res. 2016 Oct 31;20:34
pubmed: 27807476
Biomaterials. 1996 Jan;17(2):103-14
pubmed: 8624387
Circ Res. 2003 Feb 7;92(2):212-7
pubmed: 12574149
J Leukoc Biol. 2013 Jun;93(6):875-81
pubmed: 23505314
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Biomaterials. 2012 May;33(15):3792-802
pubmed: 22386919
J Exp Med. 1992 Nov 1;176(5):1375-9
pubmed: 1402682
Nat Rev Immunol. 2005 Dec;5(12):953-64
pubmed: 16322748
Proc Natl Acad Sci U S A. 2003 May 27;100(11):6712-7
pubmed: 12740443

Auteurs

Naoki Momotori (N)

Laboratory of Biomaterials, Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Jun-Ichiro Jo (JI)

Laboratory of Biomaterials, Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Yasuhiko Tabata (Y)

Laboratory of Biomaterials, Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Classifications MeSH